Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

Gustav Paumgartner; Ulrich Beuers

doi:https://doi.org/10.1016/S1089-3261(03)00135-1

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

Gustav Paumgartner, Ulrich Beuers

Research output: Contribution to journal › Article › Academic › peer-review

166 Citations (Scopus)

Abstract

Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders

Original language	English
Pages (from-to)	67-81, vi
Journal	Clinics in liver disease
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/S1089-3261(03)00135-1
Publication status	Published - 2004

Access to Document

https://doi.org/10.1016/S1089-3261(03)00135-1

Cite this

@article{52bf71c0e86b44c3bf4dc08550ce3cd2,

title = "Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease",

abstract = "Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders",

author = "Gustav Paumgartner and Ulrich Beuers",

year = "2004",

doi = "https://doi.org/10.1016/S1089-3261(03)00135-1",

language = "English",

volume = "8",

pages = "67--81, vi",

journal = "Clinics in liver disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

AU - Paumgartner, Gustav

AU - Beuers, Ulrich

PY - 2004

Y1 - 2004

N2 - Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders

AB - Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders

U2 - https://doi.org/10.1016/S1089-3261(03)00135-1

DO - https://doi.org/10.1016/S1089-3261(03)00135-1

M3 - Article

C2 - 15062194

SN - 1089-3261

VL - 8

SP - 67-81, vi

JO - Clinics in liver disease

JF - Clinics in liver disease

IS - 1

ER -